Prophylactic tumor vaccination: Comparison of effector mechanisms initiated by protein versus DNA vaccination

Journal of Immunology

Volumn 166, Issue 5, 2001, Pages 3440-3450

  Zoller M ^a   Christ, O ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; DNA VACCINE; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; GENETIC TRANSFECTION; HELPER CELL; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 0035284897     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.5.3440     Document Type: Article

References (65)

1. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones
2. Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries
3. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction
4. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells
5. MHC ligands and peptide motifs: First listing
6. In silico generation of tissue-specific and promiscuous HLA ligand databases using chips and virtual HLA class II matrices
7. Current challenges in cancer gene therapy
8. DNA vaccines: Protective immunization by parenteral, mucosal and gene-gun inoculations
9. Immunotherapy of cancer with dendritic-cell-based vaccines
10. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
11. New treatment options for patients with melanoma: Review of melanoma derived T cell epitope based peptide vaccines
12. DNA vaccines:basic mechanisms and immune responses
13. Control of immune responses by gene immunization
14. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells
15. Live attenuated Salmonella: A paradigm of mucosal vaccines
16. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine
17. Oral somatic transgene vaccination using attenuated S. thyphimurium
18. The defined attenuated Listeria monocytogenes δmp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma
19. + T-helper and a T-killer cell
20. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
21. + lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide
22. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
23. Dendritic cells: From ontogenetic orphans to myelomonocytic descendants
24. Human dendritic cells pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288) induce pairs of T cell cultures with similar phenotype and lytic activity
25. Dendritic cell vaccines for cancer immunotherapy
26. Dendritic cell-based vaccine: A promising approach for cancer immunotherapy
27. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro
28. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
29. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
30. Immunization with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells
31. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
32. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
33. T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
34. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
35. Rejection of mouse sarcoma after transfection of MHC class II genes
36. + cytotoxic T lymphocyte activation in mice
37. Help for cytotoxic T cell responses is mediated by CD40 signalling
38. + T cells in the antitumor immune response
39. Studies in listeriosis show the strong symbiosis between the innate cellular system and the T-cell response
40. Induction of TH1 and TH2 responses: A key role for the "natural" immune response?
41. A murine renal cell carcinoma
42. Cross-blocking studies with monoclonal antibodies against I-A molecules of haplotypes b, d and k
43. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines
44. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
45. The JAM test. A simple assay for DNA fragmentation and cell death
46. DNA and RNA-based vaccines: Principles, progress and prospects
47. DNA vaccines: Basic mechanism and immune responses
48. Antigen processing for amateurs and professionals
49. Protection against murine tuberculosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the 30-kDa antigen of Mycobacterium bovis BCG
50. Peripheral blood antibody-secreting cells in the evaluation of the immune response to an oral vaccine
51. Optimization, of live oral Salmonella-HIV- 1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses
52. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B
53. Salmonella vaccine carrier strains: Effective delivery system to trigger anti-tumor immunity by oral route
54. Vaccination against human cancer
55. Adoptive cellular therapy
56. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells
57. + T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity
58. Correlates of protection induced by live Aro-Salmonella typhimurium vaccines in the murine typhoid model
59. Systemic and local antibody response in mice induced by a recombinant peptide fragment from Giardia lamblia variant surface protein (VSP) H7 produced by Salmonella typhimurium vaccine strain
60. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma
61. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity
62. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor
63. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells
64. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity